BACIGUENT

Post-LOE

bacitracin

Pfizer

ANDAOPHTHALMICOINTMENT

Approved

Sep 1948

Lifecycle

Post-LOE

Competitive Pressure

30/100

Data completeness

3/8 — Basic

BACIGUENT (bacitracin) by Pfizer is clinical pharmacology: the antibiotic, bacitracin, exerts a profound action against many gram-positive pathogens, including the common streptococci and staphylococci. Approved for infection in minor:. First approved in 1948.

Drug data last refreshed 19h ago

Mechanism of Action

CLINICAL PHARMACOLOGY: The antibiotic, Bacitracin, exerts a profound action against many gram-positive pathogens, including the common Streptococci and Staphylococci. It is also destructive for certain gram-negative organisms. It is ineffective against fungi.

Indications (1)

infection in minor:

Company

Worked on BACIGUENT at Pfizer? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.